Choosing a CDMO for ADCs: Key Selection Factors

The short answer: an antibody-drug conjugate (ADC) is not one product to manufacture but three that must be joined — the antibody, the potent payload-linker, and the conjugation that connects them — so choosing a CDMO for an ADC comes down to a few decisive factors: integrated conjugation capability (to avoid a chain of technology transfers), proven high-potency containment for the cytotoxic payload, deep bioconjugation and analytical expertise (especially DAR control), sterile fill-finish of the conjugate, and a clean FDA compliance record across both biologics and high-potency small molecules. Capability, not price, drives the shortlist — and the shortlist is short.

ADCs deliver a cytotoxic drug selectively to target cells by tethering it to a monoclonal antibody. That precision makes them powerful in oncology, and it makes them unusually hard to manufacture. Here is what to weigh when selecting a partner.

Why ADCs are different

Most modalities are made by one type of facility. An ADC needs three, in sequence:

The antibody — a biologic, produced by mammalian cell culture, purified, and characterized (BLA-grade quality systems).
The payload-linker — a highly potent small molecule, synthesized under containment.
The conjugation — joining payload-linker to antibody, then purification, then sterile fill-finish of the finished conjugate.

Each step demands different expertise and equipment, and material moves between them. Every hand-off is a technology transfer and a logistics link that can fail. This is why the central question in ADC sourcing is how much of this chain can one partner do well.

The factors that actually matter

1. Integrated vs. specialist capability

An integrated CDMO that handles conjugation and fill-finish (and ideally payload or antibody supply) minimizes transfers, cold-chain shipping of intermediates, and the finger-pointing that follows a failed batch. A specialist network (antibody at one site, payload at another, conjugation at a third) can assemble best-in-class capability but multiplies coordination and comparability risk. For a clinical program on a timeline, integration usually wins; for a novel payload or antibody, a specialist may be unavoidable.

2. High-potency containment (this is non-negotiable)

ADC payloads are among the most potent compounds in pharma — typically OEB 4–5 / high-potency APIs with occupational exposure limits in the nanogram range. Handling them safely requires purpose-built containment: isolators, dedicated suites, validated cleaning, and demonstrated operator protection. Ask for the site's containment classification and cleaning-validation data. A general small-molecule suite is not adequate.

3. Bioconjugation and analytical expertise

The conjugation chemistry and its control define ADC quality. The partner must demonstrate control of the Drug-to-Antibody Ratio (DAR), free-drug levels, and aggregation, with the analytical methods to characterize them. Weak analytical capability here shows up later as batch failures and regulatory questions. Probe their conjugation platforms and their method suite before capacity or price.

4. Antibody and payload supply

Clarify who supplies what. Are you bringing the antibody and payload-linker, or does the CDMO source or make them? A partner that can supply or qualify these de-risks your chain but adds dependency. Either way, the interfaces and specifications between the three pieces must be locked down early.

5. Sterile fill-finish of the conjugate

The finished ADC is a sterile injectable made from a highly potent drug substance — so fill-finish must be both sterile and contained, a combination fewer sites can do. Confirm the partner can fill the conjugate, not just make it.

6. Regulatory and compliance track record

An ADC program spans biologics and high-potency small-molecule regulation. Screen each candidate site — not just the company — for Form 483 observations, Warning Letters, and recalls, and weigh the pattern. An open Warning Letter at the site that would make your ADC is a pause-or-walk-away signal, whatever the capability deck says.

7. Capacity and timeline

Specialized ADC capacity is constrained and books out early. Confirm real available capacity in your window, and a credible path from clinical to commercial scale at the same partner — re-transferring an ADC process late is expensive and slow.

An ADC CDMO selection checklist

Factor	What to confirm
Chain coverage	How many of antibody / payload-linker / conjugation / fill-finish in-house
Containment	OEB/OEL classification, isolators, cleaning validation, operator protection
Conjugation & analytics	Platforms, DAR control, free-drug and aggregation methods
Supply interfaces	Who supplies antibody and payload; locked specifications
Sterile + contained fill	Can they fill the conjugate, not only make it
Compliance	Site-level 483 / Warning Letter / recall history
Capacity & scale	Real availability now; clinical-to-commercial path at one site

Where this fits

ADC selection is the specialist end of a general discipline. The same axes — capability, capacity, quality systems, regulatory record — decide any CDMO or CMO engagement, and the difference between the acronyms is covered in CRO vs CDMO vs CMO. What changes for ADCs is that the bar on containment and conjugation is far higher and the candidate pool far smaller. Our CDMO selection checklist covers the general process; this piece is the ADC-specific overlay.

PharmaTek's supplier directory links FDA compliance signals to company profiles so an ADC shortlist can be screened for regulatory risk alongside capability, in one place.

Frequently asked questions

What should you look for in a CDMO for an ADC? Integrated conjugation and fill-finish capability to minimize technology transfers, proven high-potency containment for the cytotoxic payload, strong bioconjugation and analytical expertise (especially DAR control), sterile-and-contained fill-finish, and a clean FDA compliance record across biologics and high-potency small molecules. Capability drives the shortlist more than price.

Why are ADCs so hard to manufacture? An ADC is really three products joined in sequence — the antibody, the potent payload-linker, and the conjugation that connects them — each needing different facilities and expertise. Material moves between them, so every hand-off is a technology transfer and a point of failure, and the payloads are potent enough to require specialized containment.

What is DAR and why does it matter when choosing an ADC CDMO? DAR (Drug-to-Antibody Ratio) is the average number of payload molecules attached to each antibody. It affects potency, safety, and stability, so a CDMO must control it tightly and have the analytical methods to measure it. Weak DAR control is a leading cause of ADC batch failures.

Should you use one integrated CDMO or several specialists for an ADC? An integrated CDMO that covers conjugation and fill-finish reduces transfers, shipping of intermediates, and accountability gaps — usually the better choice for a clinical program on a timeline. A specialist network can assemble best-in-class capability for a novel antibody or payload but multiplies coordination and comparability risk.

Why does high-potency containment matter for ADCs? ADC payloads are typically OEB 4–5 high-potency compounds with occupational exposure limits in the nanogram range. Handling them safely requires isolators, dedicated suites, and validated cleaning — a general small-molecule facility is not adequate, and containment capability should be confirmed before anything else.

Building an ADC shortlist? Explore the supplier directory or book a demo to screen specialized partners against live FDA compliance data.

Choosing a CDMO for ADCs: The Factors That Actually Matter